Sharp drop in Angle shares following business update
AIM-listed medtech company Angle revealed that Origio, a partner involved in the development of a technology patented as EmbryoSure, has decided to cease EmbryoSure studies in a business update on Monday.
AIM-listed medtech company Angle revealed that Origio, a partner involved in the development of a technology patented as EmbryoSure, has decided to cease EmbryoSure studies in a business update on Monday.
EmbryoSure is a technology being developed to assess the viability of embryos for transfer in IVF.
Earlier in 2012, Origio was acquired by The Cooper Companies and subsequently merged with Cooper subsidiary Sage IVF. As part of a rationalisation programme, Angle said that Origio had decided to cease a number of development programmes, including the EmbryoSure study.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
As a result of Origio's decision, the intellectual property and ownership rights of EmbryoSure have reverted to Novocellus, an Angle subsidiary, and Angle's ongoing financial and management resources committed to Novocellus are being re-directed to Parasortix. Parasortix is Angle's non-invasive cancer diagnostic business.
Angle's business update stated that Angle "remains confident of EmbryoSure's clinical utility in increasing successful pregnancy rates through the selection of the most developmentally competent embryos for IVF transfer and that there is a major unmet medical need in this area."
Andrew Newland, Chief Executive and founder of Angle, commented: "We are pleased with strong continued progress with our Parsortix non-invasive cancer diagnostic business. We are maintaining a clear focus on getting a Parsortix product in the market as soon as possible. Whilst Origio's decision is disappointing, we retain the rights to EmbryoSure's intellectual property for future exploitation and this allows us to pursue a greater focus on Parsortix."
Shares in Angle fell 17.24% to 30p at 15:46 on Monday.
MF
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
UK-US trade deal announced: US cuts tariffs on UK car imports to 10%
Keir Starmer and Donald Trump have announced a UK-US trade deal, but the US president has refused to lift baseline tariffs on most UK goods. What does it mean for the UK?
-
How to use mid-caps to diversify from the US
Medium sized companies are overlooked by investors but could offer an attractive ‘sweet spot’. We consider the case for mid-caps amid market volatility.